Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyroglutamate Amyloid Beta (None)
- Target
- None
- Molecular classification
- Peptide, Modified peptide, Amyloid beta variant
01
Overview
Pyroglutamate amyloid beta (AβpE3) is a post-translationally modified form of the amyloid beta (Aβ) peptide, a key component in Alzheimer’s disease pathology. It arises from N-terminal truncation and cyclization of glutamic acid at position 3 to pyroglutamate, catalyzed by glutaminyl cyclase. This modification enhances aggregation, stability, and neurotoxicity compared to unmodified Aβ, making it a therapeutic target.
- Other names
- AβpE3pE-Aβ(3–42)AβpE3-42Pyroglutamate-modified amyloid-beta
02
Mechanism of action
Inhibition of fibril formation; Antibody-mediated clearance
03
Biological functions
AggregationFibril formationNeurotoxicityPlaque formation
04
Disease associations
Alzheimer's DiseaseNeurodegenerative disease
05
Safety considerations
Potential for off-target effects of antibodiesImmunogenicity of antibody therapiesAmyloid-related imaging abnormalities (ARIA) in clinical trials
06
Biomarkers
pE-Aβ(3) levels in cerebrospinal fluidpE-Aβ(3) levels in brain tissue (plaques)
Beyond the preview
Go deeper on Pyroglutamate Amyloid Beta (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyroglutamate Amyloid Beta (None).